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ABSTRACT 
Cerebral adenosine A2A receptors (A2ARs) are attractive therapeutic targets for neuropsychiatric disorders. 18F-
Fluoroethyl and 18F-fluoropropyl analogs of SCH442416 (18F-FESCH and 18F-FPSCH) were developed as A2AR 
specific PET ligands. Aim is to determine an appropriate compartmental model for tracer kinetics, evaluate a 
reference tissue approach and select the most suitable PET ligand. Methods: A 90 min dynamic PET with arterial 
blood sampling and metabolite analysis was acquired for 22 healthy male Wistar rats starting at 18F-FESCH (n = 12) 
and 18F-FPSCH (n = 10) injection. For each tracer, half of the number of animals was vehicle-treated while the other 
half was pretreated with the A2AR-selective antagonist KW-6002, inducing full blocking. Regional tissue 
distribution volumes (VT) were estimated by 1- and 2-tissue compartment modeling (TCM) and Logan graphical 
analysis. Midbrain, cerebellum and hippocampus were evaluated as reference region by comparing baseline VT with 
VT under full blocking conditions and comparing striatal BPND (Binding Potential) using a Simplified Reference 
Tissue Model (SRTM) with DVR-1 (Distribution Volume Ratio) for a 60 and 90 min scan duration. Results: Based 
on Akaike Information Criterion (AIC), 1TCM and 2TCM were the most appropriate models for 18F-FPSCH 
(baseline striatal VT = 3.7 ± 1.1) and 18F-FESCH (baseline striatal VT = 5.0 ± 2.0) respectively. Baseline striatal VT 
was not significantly different between both tracers. After pretreatment, striatal VT was reduced significantly with no 
significant decrease of hippocampus, midbrain and cerebellum VT. Baseline striatal SRTM BPND did not differ 
significantly from DVR-1 except for 18F-FPSCH when using a 60 min scan and midbrain as reference region while a 
Bland Altman analysis found a smaller bias for 18F-FESCH and a 60 min scan. After pretreatment, striatal SRTM 
BPND values were not significantly different from zero except for 18F-FPSCH when using hippocampus as reference 
region. Striatal SRTM BPND using midbrain or cerebellum as reference region was significantly lower for 18F-
FPSCH (range: 1.41 - 2.62) compared to 18F-FESCH (range: 1.64 - 3.36). Conclusion: Dynamic PET imaging under 
baseline and blocking conditions determined 18F-FESCH as the most suitable PET ligand for quantifying A2AR 
expression in the rat brain. Accurate quantification is achieved by a 60 min dynamic PET scan and using either 
cerebellum or midbrain as reference region. 
Keywords: Preclinical Positron Emission Tomography (µPET), cerebral adenosine A2A receptors, 18F-SCH442416 
analogs, Kinetic Analysis, Rat Brain.   
by KU Leuven University Library on January 11, 2017. For personal use only. jnm.snmjournals.org Downloaded from 
2 
 
INTRODUCTION 
Adenosine, an extracellular endogenous signaling molecule, is released to either reduce the energy demand or 
increase the energy supply to an organ or tissue which is damaged or stressed, and thereby elicits cytoprotective and 
neuromodulatory effects via four different G-protein coupled adenosine receptors (ARs) ; A1, A2A, A2B, and A3 (1-5). 
Out of these ARs, high affinity adenosine A1 and A2ARs have been extensively studied because these are well-
characterized both pharmacologically and biochemically (6). Within the human brain, A1Rs are ubiquitously present 
but high expression levels occur in the hippocampus, cerebral cortex, thalamic nuclei, and dorsal horn of spinal cord 
whereas A2ARs are restricted to the basal ganglia and particularly abundant in the striatum. Lower levels of A2ARs 
are expressed in several brain regions including hippocampus, cerebral cortex, amygdala, cerebellum, brainstem and 
hypothalamus (7-10). 
Many studies have reported a dysregulation of A2ARs in neuropsychiatric disorders such as Parkinson’s, 
Huntington’s and Alzheimer’s diseases, attention deficit hyperactivity and panic disorders, schizophrenia, pain and 
impaired sleep (11).  A number of studies suggested that A2ARs may play an important role in the regulation of 
dopaminergic and glutamatergic neurotransmission in the basal ganglia through antagonistic interactions with 
dopamine D2 receptors and by forming functional heterodimers with metabotropic glutamate receptor 5, cannabinoid 
receptor type 1, and adenosine A1Rs (12-14). Positron emission tomography (PET) with high affinity and selective 
A2AR antagonist radioligands can be used to exploit changes in A2ARs distribution and density during disease 
progression and to monitor treatment response on such changes. Furthermore, PET can be employed to assess A2AR 
occupancy by investigational drugs in the human brain, thereby providing a useful tool for the drug discovery 
process (11). 
Several PET radiotracers have been developed and evaluated for in vivo imaging of A2ARs in the brain (15-
23). We have developed 18F-FESCH and 18F-FPSCH analogs (Fig. 1) and evaluated them in healthy rats (6). 
Preliminary evaluation of these tracers showed a distribution corresponding to the known regional A2AR densities in 
the rat brain. Moreover, both tracers demonstrated slightly different but reversible kinetics with a lower nonspecific 
binding and a higher striatum-to-cerebellum ratio compared to 11C-SCH442416. Metabolite analyses indicated the 
presence of hydrophilic (radio)metabolite(s), which are not expected to cross the blood-brain barrier (6). 
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The aim of the present study was to develop a suitable tracer kinetic model for the quantification of cerebral 
A2ARs with these radiofluorinated A2AR ligands and to evaluate a reference tissue approach. In addition, it also 
reports the possible reduction in acquisition time. Based on these findings, we will select the most suitable PET 
ligand for further preclinical use.  
MATERIALS AND METHODS 
General materials and Radiosyntheses are presented in supplemental materials (available at 
http://jnm.snmjournals.org). The synthesis, radiolabeling and quality control of 18F-FESCH and 18F-FPSCH was 
described in detail previously (6). 
Small-animal PET scanning 
The animal experiments were carried out by licensed investigators in compliance with the law on Animal 
experiments of The Netherlands. The institutional Animal care and use committee of the University of Groningen 
approved the protocols. A total of 22 male outbred Wistar-Unilever rats was included in the study design, 
subdivided into a control and pretreatment group for each tracer (Table 1). Five minutes prior to i.v. tracer 
administration, animals of the pretreated group were administered a cold A2AR antagonist, KW-6002 (1 mg / kg, 50 % 
dimethylacetamide : saline (v / v)), by intraperitoneal injection (i.p.) in order to prove saturability and specific 
binding of the tracers in the brain (18,24). Since ED50 of KW-6002 in rat striatum for i.p. injection was 0.044–
0.062 mg / kg, as was demonstrated by a dose occupancy study with 11C-preladenant, administration of 1 mg / kg of 
KW-6002 by i.p. injection is expected to fully block the A2AR receptors in rat brain (23). Volume of the vehicle 
(solvent) was 1 mL / kg corresponding to a volume of 0.3 mL for an average rat with a weight of 300 g. For each 
animal a dynamic PET scan was acquired and reconstructed with 8 × 30, 3 × 60, 2 × 120, 2 × 180, 3 × 300, 5 × 600, 
and 1 × 480, and 1 × 960 s time frames. PET data were corrected for random coincidences, scatter and attenuation. 
During the scan, blood samples were drawn at 0, 5, 10, 15, 20, 30, 45, 60, 75, and 90 s and 2, 3, 5, 7, 10, 15, 30, 60, 
and 90 min after injection. Plasma samples taken at intervals of 2, 5, 10, 15, 30, 60 and 90 min were used for 
metabolite analysis using thin layer chromatography to determine two separate, average population-based metabolite 
curves for the control and pretreated animals. More information about animals, housing, anesthesia, surgery, PET 
imaging and blood sampling can be found in the supplemental materials.  
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Small-animal PET data analysis 
Time activity curves for the striatum, midbrain, cerebellum and hippocampus were extracted from the dynamic 
PET data. Kinetic analysis was performed by fitting a 1TCM and 2TCM to the time activity curves using a blood 
and metabolite corrected plasma input function. Population average values were used as input function in two 
pretreated animals of 18F-FPSCH where arterial blood sampling was not available. Besides the compartment models, 
a Logan graphical analysis of the PET data was performed with the linear fit starting at 9 min post injection. For 
both 18F-FPSCH and 18F-FESCH, VT was determined for 1TCM and 2TCM and Logan graphical analysis whereas 
1TCM and 2TCM fittings were compared using the AIC. More information about the PET data analysis can be 
found in the supplemental materials. 
Once the most appropriate compartmental model was determined, hippocampus, midbrain and cerebellum were 
evaluated as reference region by calculating striatal DVR values relative to each of these regions. Since for the 
pretreated animals blocking was expected to be complete, DVR values shouldn’t differ significantly from 1. For the 
control group, striatal DVR-1 values were compared to BPND using a SRTM for both a complete dynamic scan of 90 
min and a dynamic scan of 60 min in order to assess the feasibility of reducing the acquisition time. We excluded 
cortical areas and brain regions close to the striatum as candidate reference regions, since such regions suffer from 
spill-over effects from the striatal specific binding and from the non-specific tracer uptake in the Harderian glands or 
in skull bone because of possible tracer defluorination. 
RESULTS 
18F-FPSCH and 18F-FESCH Distribution Volume 
1TCM, 2TCM and Logan graphical analysis VT data for 18F-FPSCH and 18F-FESCH in control and pretreated 
animals are presented in Table 2. The corresponding AIC values for 1TCM and 2TCM together with representative 
fits of both tracers are presented in Fig. 2. For 18F-FPSCH, 2TCM AIC values proved to be lower than the 1TCM 
AIC values in 11 out of 48 cases, suggesting that 1TCM is most suitable model for 18F-FPSCH. However, for 18F-
FESCH, 2TCM AIC values were lower than the corresponding 1TCM values in 35 out of 40 cases, suggesting that 
2TCM is the most appropriate compartmental model for 18F-FESCH. 
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18F-FPSCH For the 18F-FPSCH VT values, a two way repeated measures  analysis of variance (ANOVA) showed 
a significant interaction between brain region and model with Bonferroni posttests revealing significant differences 
in average striatal VT values between 1TCM and the Logan plot while no significant differences between average 
1TCM and 2TCM VT values were found for all brain regions.  
As 1TCM is the preferred compartmental model to describe 18F-FPSCH tracer kinetics, 1TCM VT values were 
further analyzed using a two way repeated measures ANOVA to determine the regional effect of pretreatment. This 
analysis showed a significant interaction between brain region and pretreatment, while Bonferroni posttests 
demonstrated a significant difference in average VT values between control and pretreated animals for the striatum 
but not for hippocampus, midbrain and cerebellum. 
For the pretreated animals, 1TCM DVR values representing the striatal 18F-FPSCH uptake relative to the 
hippocampus, midbrain and cerebellum were respectively 1.10 ± 0.09, 1.04 ± 0.15 and 1.04 ± 0.11. These values 
were in all cases not significantly different from 1 (Wilcoxon Signed Rank Test, p > 0.05). 
18F-FESCH 18F-FESCH VT values were analyzed using a two way repeated measures ANOVA. This analysis 
showed a significant interaction between brain region and model with Bonferroni posttests revealing a significant 
difference in average VT values between 1TCM and 2TCM for the hippocampus and cerebellum while no significant 
differences between average Logan and 2TCM VT values were found for all brain regions. 
Since 2TCM is the compartmental model of choice for 18F-FESCH tracer kinetics,  the effect of pretreatment on 
regional 2TCM VT values was evaluated using a two way repeated measures ANOVA. This analysis showed a 
significant interaction between brain VOI and pretreatment with Bonferroni posttests demonstrating a significant 
difference in average VT values between control and pretreated animals for the striatum but not for hippocampus, 
midbrain and cerebellum. 
For the group of pretreated animals, 2TCM DVR values representing the striatal 18F-FESCH uptake relative to 
the hippocampus, midbrain and cerebellum were respectively 1.13 ± 0.20, 1.16 ± 0.43 and 1.09 ± 0.44, i.e. not 
significantly different from 1 (Wilcoxon Signed Rank Test, p > 0.05). 
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18F-FPSCH VS 18F-FESCH Using a non-parametric, two-tailed Mann-Whitney test no significant 
differences were found between striatal 18F-FESCH 2TCM VT (5.0 ± 2.0) and striatal 18F-FPSCH 1TCM VT (3.7 ± 
1.1) values in control animals (p = 0.33). 
18F-FPSCH and 18F-FESCH Binding Potential 
Striatal BPND values were calculated as 1TCM DVR–1 for 18F-FPSCH and 2TCM DVR–1 for 18F-FESCH and 
striatal BPND values for 18F-FPSCH and 18F-FESCH using SRTM and a 90 min and 60 min acquisition time interval. 
As reference region, hippocampus, midbrain and cerebellum were considered. 
CONTROL GROUP SRTM BPND values for the control group are presented in Table 3. For this group, a one 
way repeated measures ANOVA (Friedman test) for each tracer and for each candidate reference region revealed no 
significant differences between striatal BPND values calculated as DVR–1 and striatal BPND values determined using 
SRTM and a 90 min or 60 min acquisition time interval except for the 18F-FPSCH striatal BPND values using the 
midbrain as reference region. In that case, Dunn’s multiple comparison post test showed a significant difference 
between striatal BPND calculated as 1TCM DVR–1 and SRTM BPND determined using a 60 min rather than a 90 min 
acquisition time interval. 
Again for the control group, a Bland Altman comparison (% Difference) of 18F-FPSCH striatal BPND values 
calculated as 1TCM DVR–1 with the striatal BPND values for 18F-FPSCH using SRTM and a 90 min and 60 min 
acquisition time interval is presented in Table 4 for the three candidate reference regions. This is also presented for 
18F-FESCH in Table 5 where striatal BPND values calculated as 2TCM DVR–1 are compared with SRTM BPND 
values for a 90 min and 60 min acquisition time interval and for the different candidate reference regions. For visual 
assessment of the agreement between the different methods, striatal BPND values calculated as DVR–1 were also 
plotted in Fig. 3 against SRTM BPND values for a 90 min and 60 min acquisition time interval for both tracers and 
for the difference candidate reference regions.  
PRETREATMENT GROUP For the pretreatment group, the BPND values of 18F-FPSCH in the striatum using 
SRTM and  90 min or 60 min data acquisition were 0.11 ± 0.07 and 0.12 ± 0.07 (hippocampus as reference), 0.04 ± 
0.12 and 0.05 ± 0.11 (midbrain as reference) and 0.04 ± 0.10 and 0.04 ± 0.11 (cerebellum as reference). The 
corresponding BPND values for 18F-FESCH were 0.16 ± 0.21 and 0.21 ± 0.20, 0.14 ± 0.16 and 0.16 ± 0.15, and 0.04 
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± 0.28 and -0.02 ± 0.43, respectively. None of these values was significantly different from 0 (Wilcoxon Signed 
Rank Test, p > 0.05) except for the 18F-FPSCH SRTM BPND values for a 90 min and 60 min acquisition time 
interval using the hippocampus as reference region. 
18F-FPSCH VS 18F-FESCH Comparing striatal BPND values calculated as 1TCM DVR–1 for 18F-FPSCH with 
striatal BPND values calculated as 2TCM DVR–1 values for the control group and for each candidate reference 
region using a non-parametric, two-tailed Mann-Whitney test, showed significant differences for the values 
calculated for the midbrain and cerebellum while no significant difference was observed for the hippocampus. 
DISCUSSION 
We evaluated two radiofluorinated analogs of SCH442416, 18F-FPSCH and 18F-FESCH, as ligands for PET 
imaging of A2AR expression in the rat brain. Based on AIC values, a 1TCM was the most appropriate model for 
describing 18F-FPSCH kinetics while a 2TCM was the most suitable model for 18F-FESCH kinetics. The evaluation 
of the different compartment models was limited to the tracer kinetics of the subcortical regions although previous 
studies with A2AR radioligands have used the centrum semiovale (25,26) and cerebral cortex as reference region 
(27,28). However, fitting of a two compartment model to tracer uptake in the cortical regions and cerebellum proved 
to be problematic for the dynamic 18F-FPSCH scans. This was due to defluorination of the 18F-FPSCH compound, 
resulting in accumulation of activity in the skull and bone structures surrounding the brain and confounding tracer 
kinetics of cortical regions and the cerebellum with an irreversible component. For this reason, the standard template 
based cerebellar brain VOI was adjusted manually to cover only the central part of the cerebellum such that these 
confounding spillover effects were minimized.  
No significant differences were found between the striatal VT values of both tracers in control animals, although 
the average VT value in the striatum was higher for 18F-FESCH (2TCM fit) than for 18F-FPSCH (1TCM fit). For 
both tracers, striatal VT values calculated from a Logan plot were lower than VT values calculated from a 
compartment model fit, although this difference was only significant for 18F-FPSCH. This observation is in line with 
literature data which report an underestimation of VT by a Logan plot due to the impact of noise (29).  
We observed a significant reduction of the striatal VT values of both tracers after pretreatment. On the other hand, 
no significant decrease of tracer VT values in hippocampus, midbrain and cerebellum was induced by the 
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pretreatment. Moreover, the striatal DVR relative to each of these three regions after pretreatment was not 
significantly different from 1, indicating that the non-displaceable tracer binding in the striatum is identical to the 
non-displaceable tracer binding in each of these three brain regions. These findings indicate that hippocampus, 
midbrain and cerebellum can be considered as suitable candidates for a reference tissue approach to quantify 
specific tracer binding in the striatum. 
We evaluated SRTM for striatal BPND calculation in control animals using either hippocampus, midbrain or 
cerebellum as reference region and using a 60 min and 90 min dynamic PET scan. No significant differences were 
found between striatal SRTM BPND and DVR-1 values except for 18F-FPSCH using a 60 min scanning interval and 
midbrain as reference region. For the pretreatment group, striatal SRTM BPND values for 18F-FPSCH with the 
hippocampus as reference region differed significantly from zero while a value of zero was expected since full 
blocking of the A2AR was induced by pre dosing (23). Moreover for 18F-FESCH, striatal SRTM BPND values with 
the hippocampus as reference region demonstrated a considerably higher coefficient of variation (Table 3) for the 
control group compared to SRTM BPND values using the other brain regions as reference tissue. Based on these 
findings, we conclude that midbrain and cerebellum are the reference regions of choice for SRTM BPND estimation 
of 18F-FPSCH and 18F-FESCH uptake in the rat brain. Selecting the cerebellum as a reference region for SRTM 
BPND quantification of the striatal uptake of an A2AR specific PET ligand is also supported by other PET studies 
(15,19,20,30). 
A Bland Altman analysis comparing striatal SRTM BPND values with DVR–1 for 18F-FPSCH (Table 4) and for 
18F-FESCH (Table 5) using both 90 min and 60 min dynamic PET data demonstrated that both brain regions 
perform similar in terms of bias and the 95 % confidence interval. The scanning time can be reduced to 60 min with 
a limited increase in bias and 95 % confidence interval. For a reduced scanning time of 60 min, cerebellum appeared 
to perform slightly better as a reference region for 18F-FPSCH quantification while midbrain had the smallest bias 
and 95 % confidence interval for 18F-FESCH quantification. This Bland Altman analysis also proves that SRTM 
provides accurate BPND values for specific striatal 18F-FESCH uptake (Table 5) although 2TCM is the most 
appropriate compartment model for tracer 18F-FESCH kinetics in both the striatum and candidate reference regions 
and SRTM assumes 1TCM  tracer kinetics in both reference and target tissue. However, literature data have shown 
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that if the compartmental models of reference and target tissue are matched, the bias induced by SRTM is minimal 
(31,32).  
Other A2AR specific PET ligands that have been developed are 18F-MNI-444, 11C-TMSX, 11C-KW-6002, 11C-
SCH442416 and 11C-preladenant (16,23-26,28,30,33). Except for 18F-MNI-444 and 11C-preladenant, A2AR 
quantification using these tracers is challenging, because of the low specific to non-specific binding ratio or high 
extra-striatal binding. 18F-MNI-444 was tested in the rhesus monkeys and human subjects, demonstrating good brain 
penetration with BPND values ranging from 2.6 to 4.9 in A2AR-rich regions (15,16). On the other hand, 11C-
preladenant has striatal BPND values around 5.5 and fast tracer kinetics such that a 60 min acquisition time is 
sufficient for accurate A2AR quantification in a rat brain. However, 11C-labeled PET tracers have some intrinsic 
disadvantages due to the short half-life. On the other hand, 18F-FPSCH and 18F-FESCH are fluorinated compounds, 
therefore providing more flexibility in terms of imaging, and demonstrated similar tracer kinetics as 11C-preladenant 
with BPND values around 2.5. Comparing 18F-FPSCH and 18F-FESCH, striatal SRTM BPND values using either 
midbrain or cerebellum as reference region proved to be significantly lower for 18F-FPSCH compared to 18F-FESCH. 
Taking into account this finding and the Bland Altman analysis demonstrating the smaller bias for 18F-FESCH 
compared to 18F-FPSCH for a 60 min scan duration, 18F-FESCH is preferred over 18F-FPSCH for PET imaging of 
A2AR expression in the rat brain. However, for translation into a clinical setting, the presented metabolite results and 
optimal compartmental models need to be re-evaluated for 18F-FESCH brain uptake in humans, because of possible 
interspecies differences in tracer kinetics and metabolism. Since the cerebellum demonstrated low to negligible 
A2AR density in autoradiography experiments with human brain tissue (34), previous studies with A2AR-specific 
radiotracers in humans have used the cerebellum as a reference region (16). This reference tissue approach could 
also be considered for the quantification of 18F-FESCH in a clinical setting, thus avoiding the need for arterial 
sampling and metabolite analysis. 
CONCLUSION 
We evaluated two radio-fluorinated analogs of SCH442416, 18F-FPSCH and 18F-FESCH, as PET ligands for 
imaging A2AR expression in a rat brain. Full kinetic analysis using arterial blood sampling indicated 1TCM and 
2TCM as the most suitable model for 18F-FPSCH and 18F-FESCH  respectively. Dynamic PET imaging under 
baseline and full blocking conditions determined 18F-FESCH as the most suitable PET ligand for quantifying A2AR 
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expression in the rat brain. Accurate quantification of the striatal specific binding is achieved by a 60 min dynamic 
PET scan and SRTM with either cerebellum or midbrain as reference region. 
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FIGURE 1. Chemical structures of 18F-labeled SCH442416 analogs. 
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 FIGURE 2. AIC values for 1TCM and 2TCM (upper row) and a representative 1TCM 
(dotted line) and 2TCM (dashed line) fitting (lower row) for both 18F-FPSCH and 18F-
FESCH. 
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FIGURE 3. Graphical overview of the striatal BPND values calculated as DVR–1 
and using SRTM with a 90 min and 60 min scan duration. 
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 18F-FPSCH 18F-FESCH 
Group 
(# male Wistar rats) 
Vehicle-control 
(n = 6) 
Pretreated 
(n = 6) 
Vehicle-control 
(n = 5) 
Pretreated 
(n = 5) 
Body weight 
(g) 295 ± 19 293 ± 31 312 ± 14 321 ± 15 
Injected mass dose 
(nM) 0.21 ± 0.11 0.29 ± 0.27 1.13 ± 0.41 0.74 ± 0.62 
TABLE 1. Vehicle-control and pretreated group for dynamic PET scanning of a rat brain with 18F-
FPSCH and 18F-FESCH. Pretreatment was done with KW-6002 (A2AR antagonist, 1 mg / kg). Data 
are presented as mean ± SD.  
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  18F-FPSCH 18F-FESCH 
  1TCM 2TCM LGA 1TCM 2TCM LGA 
STR CTR 3.69±1.11 
(30.00%) 
3.72±1.10 
(29.53%) 
3.52±1.11 
(31.62%) 
4.80±1.69 
(35.21%) 
5.00±1.96 
(39.13%) 
4.66±1.95 
(41.96%) 
 PTR 0.98±0.38 
(38.14%) 
1.00±0.39 
(38.70%) 
0.96±0.32 
(33.46%) 
1.00±0.28 
(28.18%) 
1.22±0.26 
(21.71%) 
1.19±0.20 
(17.03%) 
HC CTR 1.13±0.29 
(25.54%) 
1.14±0.32 
(27.92%) 
1.13±0.26 
(22.89%) 
1.16±0.21 
(18.40%) 
1.29±0.29 
(22.72%) 
1.25±0.30 
(24.20%) 
 PTR 0.90±0.35 
(39.41%) 
0.91±0.37 
(40.73%) 
0.98±0.35 
(35.37%) 
0.75±0.19 
(25.03%) 
1.10±0.28 
(25.56%) 
1.00±0.20 
(19.66%) 
MB CTR 1.16±0.27 
(22.96%) 
1.17±0.26 
(22.34%) 
1.15±0.23 
(20.39%) 
1.15±0.29 
(25.13%) 
1.26±0.40 
(31.43%) 
1.22±0.37 
(30.26%) 
 PTR 0.97±0.39 
(40.16%) 
0.99±0.40 
(40.44%) 
1.07±0.49 
(45.45%) 
0.83±0.15 
(17.78%) 
1.18±0.41 
(34.63%) 
1.05±0.15 
(14.63%) 
CB CTR 1.15±0.29 
(25.63%) 
1.14±0.29 
(25.31%) 
1.07±0.29 
(26.69%) 
1.14±0.27 
(23.79%) 
1.25±0.34 
(27.50%) 
1.22±0.35 
(28.67%) 
 PTR 0.95±0.37 
(38.85%) 
0.97±0.39 
(39.90%) 
0.96±0.32 
(33.44%) 
0.82±0.13 
(15.62%) 
1.40±0.49 
(35.11%) 
1.14±0.13 
(11.47%) 
TABLE 2. 18F-FPSCH and 18F-FESCH VT values using 1TCM, 2TCM and Logan graphical 
analysis (LGA) for both the control (CTR) and pretreatment (PTR) group and for the striatum 
(STR), Hippocampus (HC), Midbrain (MB) and Cerebellum (CB). Data are presented as mean ± 
SD (CoV). 
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 18F-FPSCH 18F-FESCH 
 1TCM 
(DVR-1) 
SRTM 
(90 min) 
SRTM 
(60 min) 
2TCM 
(DVR-1) 
SRTM 
(90 min) 
SRTM 
(60 min) 
Hippocampus 2.25±0.35 
(15.77%) 
2.23±0.27 
(12.29%) 
2.35±0.22 
(9.40%) 
2.78±0.70 
(25.30%) 
2.69±0.68 
(25.33%) 
2.72±0.64 
(23.65%) 
Midbrain 2.14±0.41 
(19.28%) 
2.19±0.41 
(18.63%) 
2.29±0.33 
(14.56%) 
2.89±0.34 
(11.60%) 
2.83±0.38 
(13.38%) 
2.91±0.33 
(11.38%) 
Cerebellum 2.19±0.25 
(11.64%) 
2.28±0.21 
(9.09%) 
2.33±0.20 
(8.83%) 
2.91±0.49 
(16.94%) 
2.78±0.42 
(15.24%) 
2.80±0.34 
(12.28%) 
TABLE 3. Baseline striatal BPND values calculated as DVR–1 and using SRTM with a 90 min and 
60 min scan duration. Hippocampus, midbrain and cerebellum were considered as reference region. 
Data are presented as mean ± SD (CoV).  
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 SRTM (90 min) SRTM (60 min) 
 Hippocampus Midbrain Cerebellum Hippocampus Midbrain Cerebellum 
Bias (%) -0.4 2.8 4.4 4.9 7.8 6.9 
SD of bias 
(%) 4.6 5.2 5.8 9.0 6.8 6.4 
95% limits 
of 
agreement 
(%) 
[-9.4,8.6] [-7.5,13.0] [-7.1,15.8] [-12.8,22.5] [-5.6,21.2] [-5.7,19.4] 
TABLE 4. Bland Altman comparison of striatal BPND calculated as 1TCM DVR–1 and using SRTM for baseline 18F-
FPSCH PET with a 90 min and 60 min scan duration. Hippocampus, Midbrain and Cerebellum were considered as 
reference region. % Difference vs average was calculated. 
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 SRTM (90 min) SRTM (60 min) 
 Hippocampus Midbrain Cerebellum Hippocampus Midbrain Cerebellum 
Bias (%) -3.3 -2.3 -4.4 -1.7 0.6 -3.3 
SD of bias 
(%) 1.7 3.0 3.7 5.0 6.1 8.2 
95% limits 
of 
agreement 
(%) 
[-6.6,-0.1] [-8.1,3.5] [-11.5,2.8] [-11.4,8.1] [-11.4,12.6] [-19.4, 12.7] 
TABLE 5. Bland Altman comparison of striatal BPND calculated as 2TCM DVR–1 and using SRTM for baseline 
18F-FESCH PET with a 90 min and 60 min scan duration. Hippocampus, Midbrain and Cerebellum were 
considered as reference region. % Difference vs average was calculated. 
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MATERIALS AND METHODS 
General 
The compounds SCH442416 and KW-6002 were purchased from Axon Medchem BV 
(Groningen, The Netherlands). 1,2-Ethanediol di-p-tosylate and 1,3-Propanediol di-p-tosylate 
were acquired from Aldrich (Sigma-Aldrich, The Netherlands). All other chemicals were of 
analytical grade and were obtained from commercial suppliers such as Fluka, Rathburn, Sigma 
and Merck, and were used without further purification. 
Radiosynthesis of 18F-FESCH and 18F-FPSCH 
In brief, tracers were prepared by a two-step two-pot radiosynthetic method, starting with the 
corresponding intermediate 18F-fluorosynthons (2-18F-fluoroethyltosylate and 3-18F-
fluoropropyltosylate), followed by selective fluoroalkylation of the O-desmethyl precursor. 
Small-animal PET scanning 
Male outbred Wistar-Unilever rats were obtained from Harlan (The Netherlands). The animals 
were housed in Macrolon polycarbonate breeding cages (38 × 26 × 24 cm), maintained at a 12-h 
light / 12-h dark regime and were fed standard laboratory chow (RMH-B, The Netherlands) and 
water ad libitum. After arrival, the rats were allowed to acclimatize for at least seven days. During 
PET imaging, all animals were anesthetized with isoflurane/medical air (inhalation anesthesia, 5 % 
during induction, ≤ 2 % during maintenance) and were kept on electronic heating pads during the 
entire study period. Both a femoral artery and a femoral vein were cannulated for blood sampling 
and tracer injection, respectively. A Harvard-style syringe pump at a speed of 1mL / min was used 
for tracer injection. In addition, oxygen saturation and heart rate were measured using a pulse 
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oximeter (Nonin, The Netherlands) with an optical sensor attached to the hind leg. These 
parameters were maintained within physiological limits by manual adjustment of the anesthesia 
parameters (isoflurane concentration, gas flow).  In each scan session, two rats were scanned 
simultaneously (supine position) using a Focus 220 microPET camera (CTI, Siemens, Germany). 
The brains of both rats were placed in the field of view. Before the emission scan, a transmission 
scan of 515 s was performed using a 57Co point source. The emission scan was acquired in list 
mode for 106 min, starting at the moment the tracer entered the body of the first rat; the second 
animal was injected 16 min later. Dynamic PET data were acquired in list-mode and rebinned  into 
8 × 30, 3 × 60, 2 × 120, 2 × 180, 3 × 300, 5 × 600, and 1 × 480, and 1 × 960s time frames with one 
rebinning starting at the injection time of the first animal while the second rebinning took into 
account the delayed injection of the second animal. Time frames were reconstructed using a 2D 
ordered subsets expectation maximization algorithm (4 iterations, 16 subsets, Zoom factor, 2). The 
reconstructed images were smoothed with a 3D Gaussian filter (1.35 mm full width at half-
maximum in both directions) and split so that a separate dataset was available for each animal with 
the proper timings. During the dynamic PET scan, blood samples (volume 0.1-0.15 mL) were 
taken from the cannulation of the femoral artery. After collecting 25µL of whole blood, plasma 
(25 µL) was acquired from the remainder of the blood samples by short centrifugation (5 min at 
1000 g). Radioactivity in both 25 µL plasma and whole blood was counted on a γ-counter 
(CompuGamma 1282 CS, LKB-Wallac, Turku, Finland). 
Small-animal PET data analysis 
PET data analysis was performed using Inveon Research Workplace (Siemens Medical Solutions, 
Knoxville, TN). The summed PET time frames from each animal were co-registered to an MRI 
template of a rat brain with predefined volumes of interest. Translation, rotation and scaling were 
adjusted to visually optimize the fusion of the images. Volumes of interest were transferred from 
the MRI template to the PET data, and tissue time activity curves were extracted and rescaled to 
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standardized uptake values using measured body weight and injected dose. Compartmental models 
were fitted to the time activity curves using a blood and metabolite-corrected data from arterial 
plasma samples and uncorrected data from whole blood samples as input functions while cerebral 
blood volume was fixed to 0.036 (1). A single exponential was fitted to the parent fraction data 
while a triple exponential was fitted to the whole blood and plasma radioactivity data. PET frames 
were weighted according to the frame duration and frame mid time relative to the start of the 
acquisition. A delay parameter describing a timing offset between tissue and blood data was fitted 
simultaneously with the compartment model. 
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